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patients with HDL-c <1mmol/L, treatment with statin plus add-
on Niaspan® was compared to statin monotherapy. Niaspan®
treatment effects were taken from several clinical trials as sum-
marized in the European SPC. The second model (Markov) sim-
ulated the development of coronary heart disease events based
on the Framingham risk formulae. Direct medical costs were
accounted from a third-party payer perspective in the UK and
expressed in pounds sterling (£). Annual discount rates of 3.5%
were applied to clinical and cost outcomes. RESULTS: Niaspan®
was associated with improvements in mean discounted life
expectancy in diabetic (0.32 years) and non-diabetic cohorts
(0.29 years) compared to statin monotherapy. Similarly,
improvements in quality-adjusted life expectancy of (diabetic)
0.26 and (non-diabetic) 0.23 quality-adjusted life years (QALYs)
were projected. Niaspan® was associated with increases in mean
lifetime costs of £4492 (diabetic) and £4891 (non-diabetic)
versus statin alone. This led to incremental cost-effectiveness
ratios of £17,296 per QALY gained in the diabetic cohort and
£21,150 in the non-diabetic cohort. CONCLUSIONS: Addition
of Niaspan® to statin treatment was cost-effective by generally
accepted standards compared to statin monotherapy in patients
with persistently low HDL-c in the UK. In patients with Type-2
diabetes and an associated high risk of CHD events, add-on
therapy with Niaspan® represented better value for money than
in non-diabetic patients.
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OBJECTIVES: To project the long-term clinical and cost out-
comes associated with long-acting insulin analog treatment in
patients with type-1 diabetes in an Austrian setting. METHODS:
We used a published, validated and peer-reviewed computer sim-
ulation model of diabetes to project short-term clinical ﬁndings
to evaluate long-term outcomes including quality-adjusted life
expectancy, complication rates and direct medical costs. Clinical
data have been derived from the PREDICTIVE study, an ongoing
global post-marketing safety study, for a sub-group of patients
with type-1 diabetes receiving long-acting insulin glargine (IGlar)
in a basal/bolus treatment regimen at baseline and switched to
long-acting insulin detemir (IDet). After 12 weeks of follow up,
IDet-based basal/bolus treatment was associated with improve-
ments in HbA1c (0.25%-points lower), reduced risk of hypo-
glycemic events (by 55%), and decreased body weight (0.27kg)
compared to IGlar-based treatment. Probabilities of complica-
tions and HbA1c-dependent adjustments were derived from the
DCCT, Framingham, and WESDR studies (amongst others).
Costs of treating complications were retrieved from published
sources. Total direct costs (complications + treatment costs) were
projected over patient lifetimes. Costs and outcomes were dis-
counted at 3.5% per annum. RESULTS: Improved glycemic
control, decreased hypoglycemic events and BMI with IDet-
based basal/bolus therapy led to fewer diabetes-related compli-
cations and an increase in quality-adjusted life expectancy of
0.13 quality-adjusted life years (QALYs). IDet-based therapy was
associated with slightly higher lifetime direct costs (€394 per
patient) which led to an incremental cost-effectiveness ratio
(ICER) of €3031 per QALY gained. CONCLUSIONS: Short-
term clinical beneﬁts associated with IDet-based basal/bolus
therapy were projected to lead to improvements in quality-
adjusted life expectancy and fewer diabetes related complications
than IGlar-based regimens. Incremental cost-effectiveness analy-
sis indicated that, over patient lifetimes, IDet-based combina-
tions would represent good value for money versus IGlar-based
therapy in the Austrian setting.
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OBJECTIVES: To project long-term clinical and cost outcomes
associated with biphasic insulin aspart 30 (BIAsp 30) and oral
hypoglycemic agents (OHAs) in a Swedish setting based on the
ﬁndings of a randomized clinical trial. METHODS: A published,
validated and peer-reviewed model of diabetes was used to sim-
ulate the progression of diabetes-related complications based on
clinical trial data which showed that switching to BIAsp 30 sig-
niﬁcantly reduced HbA1c compared to continuation of OHAs in
insulin-naïve patients with Type-2 diabetes over 16 weeks (dif-
ference in HbA1c reduction 0.648%; p < 0.001). Direct medical
costs were accounted from a third party payer perspective in
Sweden and expressed in 2004 Swedish Kroner (SEK). Costs and
clinical beneﬁts were discounted at 3% annually and sensitivity
analyses were performed on treatment effect, time horizon and
discount rates. RESULTS: BIAsp 30 was projected to extend 
life expectancy (mean [standard deviation]) by 0.47 [0.22] com-
pared to OHAs (11.38 vs. 10.90 years). Quality-adjusted life
expectancy was improved with BIAsp 30 by 0.42 [0.15] quality-
adjusted life years (QALYs) versus OHAs (7.94 vs. 7.52 QALYs).
BIAsp 30 was associated with a lower cumulative incidence of
diabetes-related complications, particularly retinopathy and
nephropathy. Mean direct lifetime costs were higher in the BIAsp
30 group (SEK 286,467 [11,745]) than in patients receiving
OHAs (SEK 272,752 [12,885]), a difference of SEK 13,716
[17,030], leading to an incremental cost-effectiveness ratio of
SEK 32,736 per QALY gained. Sensitivity analysis showed that
these ﬁndings were robust under variation in a range of assump-
tions. CONCLUSIONS: Switching to BIAsp 30 was projected to
reduce the incidence of diabetes-related complications, and
improve life expectancy and quality-adjusted life expectancy,
compared to continuation of OHAs in Type-2 diabetes patients.
Switching to BIAsp 30 was projected to represent good value for
money by internationally accepted standards in the Swedish
setting.
PDB21
COST-EFFECTIVENESS ANALYSIS OF BASAL/BOLUS THERAPY
IN TYPE-1 DIABETES USING INSULIN DETEMIR + INSULIN
ASPART OR HUMAN SOLUBLE INSULIN-BASED
BASAL/BOLUS REGIMENS IN GERMANY
Valentine WJ1,Wittrup-Jensen KU2, Palmer AJ1, Roze S1
1CORE—Center for Outcomes Research, Binningen, Basel,
Switzerland; 2Novo Nordisk Pharma, Mainz, Germany
OBJECTIVES: In patients with type-1 diabetes, poor glycemic
control is associated with an increased risk of complications. A
recent clinical study provided evidence that basal/bolus treat-
ment with insulin detemir + insulin aspart (IDet/IAsp) improved
HbA1c (0.22%-points lower after 18 weeks), reduced the risk of
hypoglycemic events (by 21%), and decreased body mass index
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(BMI) (-0.3kg.m-2) in comparison to neutral protamine Hage-
dorn insulin + human soluble insulin (NPH/HSI). The aim of this
study was to project the long-term clinical and cost outcomes
associated with IDet/IAsp versus NPH/HSI basal/bolus therapy
in the German setting based on these ﬁndings. METHODS: A
published, validated and peer-reviewed model that combines
Markov sub-models and Monte Carlo simulation was used to
simulate the progression of diabetes and its complications (car-
diovascular disease, neuropathy, renal and eye disease). Transi-
tion probabilities and HbA1c-dependent adjustments were
derived from published sources. Baseline cohort characteristics
and treatment effect data were based on the clinical study. Direct
costs were retrieved from published sources and projected over
patient lifetimes from a German National Health care perspec-
tive. Costs and clinical beneﬁts were discounted at 3.5% annu-
ally. RESULTS: IDet/IAsp treatment was associated with fewer
diabetes-related complications, improved life expectancy (0.23
life years gained) and quality-adjusted life expectancy (0.21
QALYs gained) compared to NPH/HSI. Mean total lifetime costs
were €3165 per patient higher with IDet/IAsp, leading to incre-
mental cost-effectiveness ratios (ICERs) of €13,761 per life 
year and €15,071 per QALY gained. CONCLUSIONS: Short-
term clinical beneﬁts in glycemic control, hypoglycemic event
rates and BMI associated with IDet/IAsp basal/bolus therapy
were projected to lead to fewer complications, improved life
expectancy and quality-adjusted life expectancy compared to
NPH/HSI. This resulted in ICERs for IDet/IAsp versus NPH/HSI
in the range considered to represent good value for money.
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Diabetes Mellitus type-1 (DM1) is a high-incidence, chronic
disease that increases morbidity and mortality, in Spain 5000
new diagnosed patients per year have been estimated. DM1
chronic complications are the main cause of resource health care
utilization and death among diabetic patients. DM1 is one of the
most important causes of death, occupying third place for
women and seventh for men in our country. Continuous Subcu-
taneous Insulin Infusion (CSII) reduces incidence of Diabetes-
related complications when compared with Multiple Daily
Injections (MDI) for Type-1. OBJECTIVE: The aim of the study
was to project the costs and clinical beneﬁts of CSII vs. MDI in
the long term for DM1 patients in Spain. METHODS: An adap-
tation of the CORE diabetes model was carried out for the
Spanish setting. Clinical and economic data were retrieved from
published studies and SOIKOSTM Spanish’s health care cost
database. The analysis was run over a lifetime horizon from a
NHS perspective, and direct costs and beneﬁts were actualized
to euros 2004 and discounted at 3% annum. RESULTS: Pre-
liminary results showed that treatment with CSII was associated
with an improvement in life expectancy (LE) of 0.859 and 0.836
Quality-Adjusted Life-Years (QALY’s), compared to MDI. This
was accompanied by decreases in cumulative incidence of com-
plications. Mean total lifetime costs were 25,463 € more expen-
sive with CSII treatment vs. MDI. This results in an incremental
cost effectiveness ratio of 30,453 €/QALY with CSII compared
to MDI group. CONCLUSION: Improvements in glycemic
control associated with CSII vs. MDI lead to increase LE and
QoL due to reduced incidence of diabetes-related complications.
CSII is cost effective compared to MDI according to accepted
Spanish threshold.
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OBJECTIVES: In a recent randomized, controlled clinical study
in 447 patients with type-1 diabetes, use of insulin detemir (IDet)
versus neutral protamine hagedorn (NPH) insulin in a basal
(twice daily)/bolus regimen with insulin aspart (IAsp) as bolus
insulin, demonstrated that IDet/IAsp was associated with a risk
reduction of 22% for hypoglycemic events (p = 0.029), a reduc-
tion of 0.2kg in body weight (p < 0.001) and decreased systolic
blood pressure (SBP) (3mmHg, p < 0.001) versus NPH/IAsp over
6 months of treatment. No signiﬁcant difference in HbA1c was
noted. The aim of this analysis was to assess the impact of these
changes over long-term treatment with IDet/IAsp versus
NPH/IAsp. METHODS: A peer-reviewed, validated computer
simulation model was used to project these short-term ﬁndings
to evaluate long-term clinical and cost outcomes. Transition
probabilities and risk adjustments were derived from published
studies. Baseline cohort characteristics were taken from the clin-
ical trial. Total direct costs (complications + treatment costs)
were derived from published sources and projected over patients’
lifetimes from a German National Health care perspective. Costs
and clinical beneﬁts were discounted at 3.5% annually.
RESULTS: Decreased incidence of hypoglycemic events,
improved BMI and SBP associated with IDet/IAsp treatment 
led to fewer diabetes-related complications, increased life
expectancy (0.15 years) and improved quality-adjusted life
expectancy (0.22 QALYs) compared to NPH/IAsp. Mean total
lifetime costs were €1204 per patient higher in the IDet/IAsp
treatment arm than in the NPH/IAsp group, leading to incre-
mental cost-effectiveness ratios of €8027 per LYG and €5473 per
QALY gained. CONCLUSIONS: Short-term clinical improve-
ments associated with IDet/IAsp were projected to lead to a
lower incidence of complications, improved life expectancy and
quality-adjusted life expectancy compared to NPH/IAsp. Reduc-
tions in the cost of complications partially offset the costs of
IDet/IAsp treatment, leading to incremental cost-effectiveness
ratios within the range considered to represent good value for
money.
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OBJECTIVES: To evaluate the long-term clinical and cost out-
comes associated with insulin aspart + metformin (IAsp/MET)
versus human insulin + metform (HI/MET) in patients with
Type-2 diabetes in a German setting based on the ﬁndings of the
PHAZIT clinical trial. METHODS: Long-term outcomes were
